Spots Global Cancer Trial Database for recurrent ovarian carcinoma

Every month we try and update this database with for recurrent ovarian carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT03691376	Platinum-Resist... Platinum-Resist... Platinum-Resist... Platinum-Sensit... Platinum-Sensit... Platinum-Sensit... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Refractory Fall... Refractory Ovar... Refractory Prim...	Aldesleukin Autologous NY-E... Cellular Therap... Melphalan	18 Years -	Roswell Park Cancer Institute
A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma	NCT00671788	Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Dasatinib Laboratory Biom...	18 Years -	GOG Foundation
Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer	NCT02996825	Recurrent Breas... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Triple-Negative...	Gemcitabine Gemcitabine Hyd... Laboratory Biom... Mirvetuximab So... Pharmacological...	-	City of Hope Medical Center
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT02839707	Fallopian Tube ... Ovarian High Gr... Ovarian Seromuc... Primary Periton... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Plati... Recurrent Plati... Recurrent Plati... Recurrent Prima... Recurrent Prima... Recurrent Prima... Recurrent Prima...	Atezolizumab Bevacizumab Computed Tomogr... Pegylated Lipos... Quality-of-Life...	18 Years -	National Cancer Institute (NCI)
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT04781088	Platinum-Resist... Platinum-Resist... Platinum-Resist... Recurrent Endom... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Lenvatinib Paclitaxel Pembrolizumab	18 Years -	Ohio State University Comprehensive Cancer Center
Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	NCT01074411	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Brenner... Ovarian Clear C... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Serous ... Ovarian Transit... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Undifferentiate... Undifferentiate...	Bortezomib Carboplatin Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT02446600	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima...	Biospecimen Col... Carboplatin Cediranib Malea... Computed Tomogr... Echocardiograph... Gemcitabine Gemcitabine Hyd... Laboratory Biom... Magnetic Resona... Multigated Acqu... Olaparib Paclitaxel Pegylated Lipos... Pharmacological... Quality-of-Life...	18 Years -	National Cancer Institute (NCI)
Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer	NCT00979992	Ovarian Clear C... Recurrent Ovari...	Laboratory Biom... Sunitinib Malat...	18 Years -	National Cancer Institute (NCI)
High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy	NCT04201561	Chemotherapy-in... Recurrent Ovari... Ovarian Cancer Fallopian Tube ... Primary Periton...	sodium selenite... Normal saline Chemotherapy	19 Years - 80 Years	Seoul National University Hospital
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT03586661	Deleterious BRC... Deleterious BRC... Endometrial Ade... High Grade Ovar... Platinum-Resist... Primary Periton... Progressive Dis... Recurrent Endom... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Copanlisib Niraparib	18 Years -	M.D. Anderson Cancer Center
EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	NCT01118052	Fallopian Tube ... Primary Periton... Recurrent Ovari...	Laboratory Biom... PEG-PEI-cholest...	18 Years -	GOG Foundation
Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers	NCT03924245	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... High Grade Fall... High Grade Ovar... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Primary Periton... Recurrent Endom... Recurrent Ovari... Recurrent Prima...	Entinostat Olaparib	18 Years -	Vanderbilt-Ingram Cancer Center
Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT02901899	Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Guadecitabine Laboratory Biom... Pembrolizumab	18 Years -	Northwestern University
Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer	NCT05672095	Platinum-Resist... Platinum-Resist... Platinum-Resist... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Biopsy Biospecimen Col... Niraparib Questionnaire A... Selenium	18 Years -	City of Hope Medical Center
Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent	NCT02470559	Malignant Ovari... Malignant Ovari... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar...	Aldesleukin HER2Bi-Armed Ac... Laboratory Biom... Sargramostim	18 Years -	Barbara Ann Karmanos Cancer Institute
Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy	NCT01492920	Fatigue Malignant Ovari... Neuropathy Neurotoxicity S... Ovarian Brenner... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Serous ... Pain Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Acetyl-L-Carnit... Placebo Questionnaire A... Quality-of-Life...	18 Years -	GOG Foundation
Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT02315430	Fallopian Tube ... Ovarian Clear C... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Cabozantinib S-... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer	NCT00072566	Primary Periton... Recurrent Ovari... Stage IV Ovaria...	Bevacizumab Cyclophosphamid... Laboratory Biom...	-	National Cancer Institute (NCI)
A Study of FRaDCs for Ovarian Cancer	NCT05920798	Fallopian Tube ... Primary Periton... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Recurrent Prima... Recurrent Prima... Recurrent Prima...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Multi-epitope F... Pembrolizumab Pheresis	18 Years -	Mayo Clinic
TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer	NCT01294293	Malignant Ovari... Ovarian Brenner... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Undifferentiate...	TLR8 Agonist VT... Diagnostic Labo... Pharmacological... Pegylated Lipos... Paclitaxel	18 Years -	GOG Foundation
A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer	NCT04092270	Endometrial Hig... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... FIGO Grade 1 En... FIGO Grade 2 En... Ovarian High Gr... Ovarian Seromuc... Ovarian Undiffe... Platinum-Sensit... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Recurrent Fallo... Recurrent Low G... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Recurrent Prima...	Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Pegylated Lipos... Peposertib	18 Years -	National Cancer Institute (NCI)
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene	NCT03602079	HER2-positive B... HER2 Gene Mutat... HER-2 Gene Ampl... HER2 Positive G... Salivary Gland ... Salivary Gland ... Salivary Gland ... Salivary Gland ... Lung Cancer Colo-rectal Can... Rare Diseases Solid Tumor Recurrent Gastr... Recurrent Colon... Recurrent Breas... Head and Neck C... Head and Neck C... Bladder Cancer Cervical Cancer Liver Cancer Bile Duct Cance... Urologic Cancer Pancreatic Canc... Prostate Cancer Recurrent Prost... Rectal Cancer Recurrent Ovari... Recurrent Renal... Rectal Cancer S... Rectal Cancer S... Rectal Cancer S... Skin Cancer Mouth Cancer Lip Cancer Stag... Tongue Cancer Breast Neoplasm... Larynx Cancer Tonsil Cancer Palate Cancer Mucoepidermoid ... Primary Periton... Mucinous Adenoc... Mucinous Breast... Cholangiocarcin...	A166	18 Years -	Klus Pharma Inc.
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas	NCT03449108	Bone Sarcoma Dedifferentiate... Giant Cell Tumo... Malignancy in G... Malignant Solid... Ovarian Carcino... Platinum-Resist... Poorly Differen... Recurrent Osteo... Recurrent Ovari... Refractory Oste... Soft Tissue Sar... Thyroid Gland A... Thyroid Gland S... Undifferentiate... Triple Negative...	Aldesleukin Autologous Tumo... Autologous Tumo... Cyclophosphamid... Fludarabine Ipilimumab Nivolumab Quality-of-Life... Questionnaire A...	16 Years - 70 Years	M.D. Anderson Cancer Center
Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer	NCT03542669	Recurrent Ovari... Platinum-resist...	6B11-OCIK Injec... Doxorubicin	18 Years - 70 Years	Peking University People's Hospital
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	NCT04514484	Advanced Differ... Advanced Head a... Advanced Hepato... Advanced Kaposi... Advanced Lung N... Advanced Lung S... Advanced Malign... Advanced Melano... Advanced Ovaria... Advanced Prosta... Advanced Renal ... Advanced Thyroi... Advanced Triple... Advanced Urothe... Anatomic Stage ... Anatomic Stage ... Castration-Resi... Clinical Stage ... Clinical Stage ... HIV Infection Metastatic Diff... Metastatic Head... Metastatic Hepa... Metastatic Kapo... Metastatic Lung... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Ovar... Metastatic Pros... Metastatic Rena... Metastatic Thyr... Metastatic Trip... Metastatic Urot... Recurrent Diffe... Recurrent Head ... Recurrent Hepat... Recurrent Kapos... Recurrent Lung ... Recurrent Lung ... Recurrent Malig... Recurrent Melan... Recurrent Ovari... Recurrent Prost... Recurrent Renal... Recurrent Thyro... Recurrent Tripl... Recurrent Uroth... Refractory Diff... Stage III Diffe... Stage III Hepat... Stage III Lung ... Stage III Ovari... Stage III Prost... Stage III Renal... Stage III Thyro... Stage IV Differ... Stage IV Hepato... Stage IV Lung C... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Thyroi...	Biospecimen Col... Cabozantinib S-... Computed Tomogr... Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer	NCT01720173	Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Dalantercept Laboratory Biom...	18 Years -	GOG Foundation
Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	NCT01074411	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Brenner... Ovarian Clear C... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Serous ... Ovarian Transit... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Undifferentiate... Undifferentiate...	Bortezomib Carboplatin Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT01540565	BRCA1 Mutation ... BRCA2 Mutation ... Ovarian Epithel... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Laboratory Biom... Veliparib	18 Years -	National Cancer Institute (NCI)
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer	NCT01010126	Adult Hepatocel... Advanced Adult ... Endometrial Ser... Localized Non-R... Lung Carcinoid ... Malignant Pancr... Malignant Pancr... Malignant Pancr... Malignant Pancr... Metastatic Dige... Ovarian Carcino... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Pancreatic Alph... Pancreatic Beta... Pancreatic Delt... Pancreatic G-Ce... Pancreatic Poly... Recurrent Adult... Recurrent Diges... Recurrent Fallo... Recurrent Ovari... Recurrent Pancr... Recurrent Prima... Recurrent Uteri... Regional Digest... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIA Uter... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIB Uter... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IIIC Uter... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IVA Uteri... Stage IVB Uteri... Uterine Carcino...	Bevacizumab Temsirolimus	18 Years -	National Cancer Institute (NCI)
Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer	NCT02996825	Recurrent Breas... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Triple-Negative...	Gemcitabine Gemcitabine Hyd... Laboratory Biom... Mirvetuximab So... Pharmacological...	-	City of Hope Medical Center
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT02923739	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Malignant Ovari... Ovarian Adenoca... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Bevacizumab Emactuzumab Laboratory Biom... Paclitaxel Pharmacological...	18 Years -	M.D. Anderson Cancer Center
Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT03026062	Platinum-Resist... Platinum-Resist... Platinum-Resist... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Refractory Fall... Refractory Ovar... Refractory Prim...	Durvalumab Tremelimumab	18 Years -	M.D. Anderson Cancer Center
Clonal Hematopoiesis in Ovarian Cancer Survivors and Risk of Secondary Blood Cancers	NCT06295965	Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Non-Interventio...	-	University of Washington
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT02101775	Ovarian Brenner... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Serous ... Ovarian Undiffe... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Adavosertib Gemcitabine Hyd... Laboratory Biom... Pharmacological... Placebo Adminis... Questionnaire A...	18 Years -	National Cancer Institute (NCI)
Register to Describe the Treatment Pattern of Platinum-sensitive Relapsed Epithelial Ovarian Cancer Patients in Austria	NCT04369352	Recurrent Ovari...		18 Years - 99 Years	Medical University Innsbruck
Collecting Tumor Samples From Patients With Gynecological Tumors	NCT00897442	Borderline Ovar... Borderline Ovar... Cervical Adenoc... Cervical Adenos... Cervical Small ... Cervical Squamo... Childhood Embry... Childhood Malig... Endometrioid St... Gestational Tro... Malignant Mesot... Malignant Ovari... Melanoma Neoplasm of Unc... Ovarian Brenner... Ovarian Clear C... Ovarian Serous ... Paget Disease o... Recurrent Cervi... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Recurrent Vagin... Recurrent Vulva... Stage I Ovarian... Stage I Uterine... Stage I Vaginal... Stage I Vulvar ... Stage IA Cervic... Stage IA Fallop... Stage IA Ovaria... Stage IA Ovaria... Stage IB Cervic... Stage IB Fallop... Stage IB Ovaria... Stage IB Ovaria... Stage IC Fallop... Stage IC Ovaria... Stage IC Ovaria... Stage II Ovaria... Stage II Uterin... Stage II Vagina... Stage II Vulvar... Stage IIA Cervi... Stage IIA Fallo... Stage IIA Ovari... Stage IIA Ovari... Stage IIB Cervi... Stage IIB Fallo... Stage IIB Ovari... Stage IIB Ovari... Stage IIC Fallo... Stage IIC Ovari... Stage IIC Ovari... Stage III Borde... Stage III Cervi... Stage III Uteri... Stage III Vagin... Stage III Vulva... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Border... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IV Uterin... Stage IVA Cervi... Stage IVA Vagin... Stage IVB Cervi... Stage IVB Vagin... Stage IVB Vulva... Uterine Corpus ... Uterine Corpus ... Vulvar Squamous...	Laboratory Biom...	-	GOG Foundation
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial	NCT05564377	Advanced Malign... Anatomic Stage ... Anatomic Stage ... Locally Advance... Malignant Femal... Metastatic HER2... Metastatic Mali... Recurrent Endom... Recurrent Fallo... Recurrent Malig... Recurrent Malig... Recurrent Ovari... Recurrent Prima... Unresectable HE... Unresectable Ma...	Alpelisib Binimetinib Biopsy Biospecimen Col... Bone Marrow Asp... Bone Scan Computed Tomogr... Echocardiograph... Fluorouracil Fulvestrant Ipatasertib Leucovorin Magnetic Resona... Multigated Acqu... Mutation Carrie... Neratinib Malea... Nilotinib Hydro... Olaparib Oxaliplatin Paclitaxel Palbociclib Panitumumab Positron Emissi... Selumetinib Sul... Sotorasib	-	National Cancer Institute (NCI)
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT02627443	Metastatic Fall... Metastatic Ovar... Metastatic Prim... Ovarian Endomet... Ovarian High Gr... Platinum-Sensit... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar...	Berzosertib Carboplatin Gemcitabine Hyd... Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery	NCT00410553	Adult Solid Neo... Recurrent Ovari... Recurrent Uteri... Stage III Ovari... Stage III Uteri... Stage IV Ovaria... Stage IV Uterin...	Eribulin Mesyla... Gemcitabine Hyd...	18 Years -	National Cancer Institute (NCI)
Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer	NCT05310344	Ovarian Carcino... Platinum-resist... Recurrent Ovari... Albumin-bound P... Bevacizumab Survival Outcom... Adverse Events	Albumin-bound p...	18 Years - 75 Years	Peking Union Medical College Hospital
Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer	NCT01716715	Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Cabozantinib S-... Laboratory Biom... Paclitaxel	18 Years -	National Cancer Institute (NCI)
Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer	NCT02283658	Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Undifferentiate...	Everolimus Laboratory Biom... Letrozole	18 Years -	Mayo Clinic
Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT04387227	Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Carboplatin Pembrolizumab Computed Tomogr... Magnetic Resona... Biospecimen Col...	18 Years -	University of Washington
Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer	NCT02111941	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Undifferentiate... Undifferentiate...	Laboratory Biom... Multi-epitope F...	18 Years -	Mayo Clinic
Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy	NCT00602277	Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Laboratory Biom... Wild-type Reovi...	18 Years -	National Cancer Institute (NCI)
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial	NCT05554328	Recurrent Endom... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Biopsy Biospecimen Col... Bone Marrow Asp... Computed Tomogr... Echocardiograph... Multigated Acqu... Olaparib Selumetinib Sul...	18 Years -	National Cancer Institute (NCI)
Collecting Tumor Samples From Patients With Gynecological Tumors	NCT00897442	Borderline Ovar... Borderline Ovar... Cervical Adenoc... Cervical Adenos... Cervical Small ... Cervical Squamo... Childhood Embry... Childhood Malig... Endometrioid St... Gestational Tro... Malignant Mesot... Malignant Ovari... Melanoma Neoplasm of Unc... Ovarian Brenner... Ovarian Clear C... Ovarian Serous ... Paget Disease o... Recurrent Cervi... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Recurrent Vagin... Recurrent Vulva... Stage I Ovarian... Stage I Uterine... Stage I Vaginal... Stage I Vulvar ... Stage IA Cervic... Stage IA Fallop... Stage IA Ovaria... Stage IA Ovaria... Stage IB Cervic... Stage IB Fallop... Stage IB Ovaria... Stage IB Ovaria... Stage IC Fallop... Stage IC Ovaria... Stage IC Ovaria... Stage II Ovaria... Stage II Uterin... Stage II Vagina... Stage II Vulvar... Stage IIA Cervi... Stage IIA Fallo... Stage IIA Ovari... Stage IIA Ovari... Stage IIB Cervi... Stage IIB Fallo... Stage IIB Ovari... Stage IIB Ovari... Stage IIC Fallo... Stage IIC Ovari... Stage IIC Ovari... Stage III Borde... Stage III Cervi... Stage III Uteri... Stage III Vagin... Stage III Vulva... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Border... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IV Uterin... Stage IVA Cervi... Stage IVA Vagin... Stage IVB Cervi... Stage IVB Vagin... Stage IVB Vulva... Uterine Corpus ... Uterine Corpus ... Vulvar Squamous...	Laboratory Biom...	-	GOG Foundation
MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer	NCT02068794	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Malignant Ovari... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Laboratory Biom... Mesenchymal Ste... Oncolytic Measl...	18 Years -	Mayo Clinic
PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT02948101	Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Anti-CSF1 Monoc... Cyclophosphamid... Laboratory Biom...	18 Years -	M.D. Anderson Cancer Center
Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT03029598	Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Carboplatin Laboratory Biom... Pembrolizumab	18 Years -	University of Washington
Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients	NCT04213794	Malignant Abdom... Malignant Pelvi... Recurrent Colon... Recurrent Desmo... Recurrent Fallo... Recurrent Gastr... Recurrent Lipos... Recurrent Malig... Recurrent Ovari... Recurrent Prima... Recurrent Recta... Recurrent Rhabd... Recurrent Sarco... Refractory Colo... Refractory Desm... Refractory Fall... Refractory Gast... Refractory Lipo... Refractory Mali... Refractory Ovar... Refractory Prim... Refractory Rect... Refractory Rhab... Refractory Sarc... Resectable Lipo... Resectable Mali... Resectable Sarc...	Cisplatin Cytoreductive S... Doxorubicin Hyperthermic In... Sodium Thiosulf... Computed Tomogr... Magnetic Resona... Positron Emissi... Biospecimen Col...	1 Year - 25 Years	Mayo Clinic
Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer	NCT03690739	Recurrent Ovari...	Carboplatin Gemcitabine Bevacizumab PLD Paclitaxel PLD Trabectedin Cisplatin	18 Years -	AGO Research GmbH
Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer	NCT02520115	Adnexal Mass Borderline Ovar... Ovarian Clear C... Ovarian Endomet... Ovarian Neoplas... Ovarian Serous ... Recurrent Ovari...	Dexamethasone Laboratory Biom... Valproic Acid	18 Years -	Barbara Ann Karmanos Cancer Institute
A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer	NCT01283035	Ovarian Sarcoma Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Akt Inhibitor M... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	NCT00888615	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Brenner... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Elesclomol Sodi... Paclitaxel	18 Years -	GOG Foundation
Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT02315430	Fallopian Tube ... Ovarian Clear C... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Cabozantinib S-... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer	NCT03348631	Recurrent Endom... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Uteri...	Computed Tomogr... Magnetic Resona... Tazemetostat	18 Years -	National Cancer Institute (NCI)
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT02627443	Metastatic Fall... Metastatic Ovar... Metastatic Prim... Ovarian Endomet... Ovarian High Gr... Platinum-Sensit... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar...	Berzosertib Carboplatin Gemcitabine Hyd... Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers	NCT03968406	Malignant Femal... Recurrent Cervi... Recurrent Endom... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Vagin... Stage IV Cervic... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IV Uterin... Stage IV Vagina... Stage IVA Cervi... Stage IVA Fallo... Stage IVA Ovari... Stage IVA Prima... Stage IVA Uteri... Stage IVA Vagin... Stage IVB Cervi... Stage IVB Fallo... Stage IVB Ovari... Stage IVB Prima... Stage IVB Uteri... Stage IVB Vagin...	Quality-of-Life... Radiation Thera... Talazoparib	18 Years -	M.D. Anderson Cancer Center
LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma	NCT02083536	Ovarian Cancer Ovarian Carcino... Recurrent Ovari... Recurrent Ovari...	Low Dose Fracti... Docetaxel	18 Years - 80 Years	University of Miami
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors	NCT02142803	Adult Glioblast... Endometrial Cle... Endometrial Ser... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Solid Neoplasm Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar...	Bevacizumab Laboratory Biom... Pharmacological... Sapanisertib	18 Years -	National Cancer Institute (NCI)
Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT03029598	Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Carboplatin Laboratory Biom... Pembrolizumab	18 Years -	University of Washington
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer	NCT05231122	Ovarian Clear C... Platinum-Sensit... Recurrent Endom... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Plati... Recurrent Prima... Recurrent Prima... Recurrent Prima... Recurrent Prima...	Anti-CD40 Agoni... Bevacizumab Pembrolizumab Quality-of-Life... Questionnaire A...	18 Years -	Roswell Park Cancer Institute
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer	NCT01264432	Adult Solid Neo... Peritoneal Carc... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Laboratory Biom... Quality-of-Life... Radiation Thera... Veliparib	18 Years -	National Cancer Institute (NCI)
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability	NCT03428802	BRCA1 Gene Muta... BRCA2 Gene Muta... Locally Advance... Metastatic Mali... POLD1 Gene Muta... POLE Gene Mutat... Recurrent Malig... Recurrent Ovari... Stage III Breas... Stage III Ovari... Stage IIIA Brea... Stage IIIA Ovar... Stage IIIB Brea... Stage IIIB Ovar... Stage IIIC Brea... Stage IIIC Ovar... Stage IV Breast... Stage IV Ovaria... Stage IVA Ovari... Stage IVB Ovari...	Laboratory Biom... Pembrolizumab	18 Years -	Rutgers, The State University of New Jersey
Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer	NCT03690739	Recurrent Ovari...	Carboplatin Gemcitabine Bevacizumab PLD Paclitaxel PLD Trabectedin Cisplatin	18 Years -	AGO Research GmbH
Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer	NCT05672095	Platinum-Resist... Platinum-Resist... Platinum-Resist... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Biopsy Biospecimen Col... Niraparib Questionnaire A... Selenium	18 Years -	City of Hope Medical Center
CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer	NCT00045682	Primary Periton... Recurrent Ovari...	Paclitaxel Poli...	18 Years -	GOG Foundation
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT02595892	Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Berzosertib Gemcitabine Gemcitabine Hyd...	18 Years -	National Cancer Institute (NCI)
Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer	NCT03690739	Recurrent Ovari...	Carboplatin Gemcitabine Bevacizumab PLD Paclitaxel PLD Trabectedin Cisplatin	18 Years -	AGO Research GmbH
LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma	NCT02083536	Ovarian Cancer Ovarian Carcino... Recurrent Ovari... Recurrent Ovari...	Low Dose Fracti... Docetaxel	18 Years - 80 Years	University of Miami
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer	NCT03277482	Recurrent Gynec... Metastatic Cerv... Metastatic Ovar... Metastatic Vagi... Metastatic Vulv... Metastatic Endo... Recurrent Cervi... Recurrent Ovari... Recurrent Vagin... Recurrent Vulva... Recurrent Endom...	Durvalumab Tremelimumab Radiation Thera...	18 Years -	Dana-Farber Cancer Institute
PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT02948101	Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Anti-CSF1 Monoc... Cyclophosphamid... Laboratory Biom...	18 Years -	M.D. Anderson Cancer Center
A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer	NCT04999605	Ovarian Neoplas... Recurrent Ovari... Relapsed Ovaria... Ovarian Cancer	AK112 low dose AK112 medium do... AK112 high dose	18 Years - 75 Years	Akeso
Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients	NCT03539406	Recurrent Ovari... Recurrent Fallo... Recurrent Prima...	UCB-NK cells Chemotherapy	18 Years - 75 Years	Radboud University Medical Center
Whole Abdomen Radiation in Conjunction With Intraperitoneal Chemotherapy for the Treatment of Small Volume Recurrent Ovarian Carcinoma Limited to the Peritoneal Cavity	NCT00942838	Recurrent Ovari...	Cisplatin Whole Abdomen R...	18 Years -	University of Utah
EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	NCT01489371	Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Ovarian Undiffe... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Laboratory Biom... PEG-PEI-cholest... Pegylated Lipos...	18 Years -	GOG Foundation
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT02595892	Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Berzosertib Gemcitabine Gemcitabine Hyd...	18 Years -	National Cancer Institute (NCI)
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer	NCT03552471	BRCA1 Gene Muta... BRCA2 Gene Muta... Folate Receptor... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Recurrent Uteri... Recurrent Uteri... Platinum Resist...	Laboratory Biom... Mirvetuximab So... Pharmacokinetic... Rucaparib Camsy...	18 Years -	Ohio State University Comprehensive Cancer Center
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer	NCT02502266	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Cediranib Cediranib Malea... Computed Tomogr... Magnetic Resona... Olaparib Paclitaxel Pegylated Lipos... Questionnaire A... Topotecan Topotecan Hydro...	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: